Skip to main content

Intermittent Claudication

10
Pipeline Programs
8
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
2
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

B. Braun
B. BraunGermany - Melsungen
1 program
1
6 mm Uni-graft®Phase 41 trial
Active Trials
NCT00300690Completed400Est. Jan 1999
Genovate Biotechnology
Genovate BiotechnologyTaiwan - Hsinchu
6 programs
5
1
Cilostazol 200 mgPhase 31 trial
Cilostazol 100 mgPhase 11 trial
Cilostazol 100 mgPhase 11 trial
Cilostazol 100 mgPhase 11 trial
Cilostazol Tablet 100 mgPhase 11 trial
+1 more programs
Active Trials
NCT03480321Completed21Est. Jun 2018
NCT05191862Terminated19Est. May 2022
NCT03864666Completed28Est. May 2019
+3 more trials
GenFleet Therapeutics
GenFleet TherapeuticsChina - Shanghai
1 program
1
GFH312Phase 21 trial
Active Trials
NCT05618691Withdrawn0Est. May 2024
NicOx
NicOxFrance - Biot
1 program
1
NCX-4016Phase 21 trial
Active Trials
NCT01256775Completed442Est. Apr 2005
Otsuka
OtsukaJapan - Tokushima
1 program
1
CilostazolPhase 11 trial
Active Trials
NCT00773630Completed44Est. Mar 2009
Sanofi
SanofiPARIS, France
1 program
Ad2/HIF-1α/VP16PHASE_21 trial
Active Trials
NCT00117650Completed289Est. Mar 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
B. Braun6 mm Uni-graft®
Genovate BiotechnologyCilostazol 200 mg
GenFleet TherapeuticsGFH312
SanofiAd2/HIF-1α/VP16
NicOxNCX-4016
Genovate BiotechnologyCilostazol Tablet 100 mg
Genovate BiotechnologyCilostazol Tablet 100 mg
Genovate BiotechnologyCilostazol 100 mg
Genovate BiotechnologyCilostazol 100 mg
Genovate BiotechnologyCilostazol 100 mg
OtsukaCilostazol

Clinical Trials (11)

Total enrollment: 1,322 patients across 11 trials

NCT00300690B. Braun6 mm Uni-graft®

Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft (PopUp)

Start: Oct 1993Est. completion: Jan 1999400 patients
Phase 4Completed
NCT06886620Genovate BiotechnologyCilostazol 200 mg

Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication

Start: Mar 2016Est. completion: Feb 201714 patients
Phase 3Terminated
NCT05618691GenFleet TherapeuticsGFH312

A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)

Start: Dec 2022Est. completion: May 20240
Phase 2Withdrawn
NCT00117650SanofiAd2/HIF-1α/VP16

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

Start: Feb 2005Est. completion: Mar 2010289 patients
Phase 2Completed
NCT01256775NicOxNCX-4016

Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)

Start: Sep 2003Est. completion: Apr 2005442 patients
Phase 2Completed
NCT06167265Genovate BiotechnologyCilostazol Tablet 100 mg

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers

Start: Nov 2023Est. completion: Jan 202440 patients
Phase 1Completed
NCT05466734Genovate BiotechnologyCilostazol Tablet 100 mg

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Start: Jul 2022Est. completion: Sep 202225 patients
Phase 1Completed
NCT05191862Genovate BiotechnologyCilostazol 100 mg

Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers

Start: Apr 2022Est. completion: May 202219 patients
Phase 1Terminated
NCT03864666Genovate BiotechnologyCilostazol 100 mg

Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Start: Feb 2019Est. completion: May 201928 patients
Phase 1Completed
NCT03480321Genovate BiotechnologyCilostazol 100 mg

Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Start: Mar 2018Est. completion: Jun 201821 patients
Phase 1Completed
NCT00773630OtsukaCilostazol

A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions

Start: Dec 2008Est. completion: Mar 200944 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.